Get started
Work

Post Hoc Analysis of Defibrotide for Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Post-Hematopoietic Stem Cell Transplantation in Subgroups of Patients with and Without Leukemia

Year: 2017
Type: article
Abstract: Introduction: Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a life-threatening complication of conditioning for hematopoietic stem cell transplant (HSCT). Reported incidence post-HSCT is ~13.7%. In patients with concomitant multi-organ dysfunction (MOD; eg, renal or pulmonary), mortality may be >80%. Defibrotide is approved in the US to treat hepatic VOD/SOS with renal and/or pulmonary dysfunction post-HSCT, and in the EU to treat severe hepatic VOD/SOS post-HSCT.
DOI: 10.1016/j.bbmt.2016.12.213
Authors: Paul G. Richardson, Angela R. Smith, Brandon M. Triplett, Nancy A. Kernan, Stephan A. Grupp, Joseph H. Antin, Leslie Lehmann, Robert Ryan, Robin Hume, William Tappe, Robert J. Soiffer
Institutions: Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, University of Minnesota, St. Jude Children's Research Hospital, Memorial Sloan Kettering Cancer Center, Children's Hospital of Philadelphia, Jazz Pharmaceuticals (United States)
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2591025850
FWCI:
Cites:
Cited by:
Related to: 10